{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:39:50Z","timestamp":1791664790656,"version":"4.3.4"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"am","delay-in-days":282,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["R01 AR073208"],"award-info":[{"award-number":["R01 AR073208"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["T32 AR048522-18"],"award-info":[{"award-number":["T32 AR048522-18"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["K23AR075872"],"award-info":[{"award-number":["K23AR075872"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["K24 AR080217"],"award-info":[{"award-number":["K24 AR080217"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["K23AR075898"],"award-info":[{"award-number":["K23AR075898"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015629","name":"Jerome L Greene Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015629","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.semarthrit.2024.152460","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T21:51:19Z","timestamp":1714773079000},"page":"152460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosis"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-7438","authenticated-orcid":false,"given":"Rachel S","family":"Wallwork","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J","family":"Kotzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Mecoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Clifton O","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick M","family":"Wigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker C","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana D","family":"DiRenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1139-2009","authenticated-orcid":false,"given":"Ami A","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.semarthrit.2024.152460_bib0001","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"New England journal of medicine"},{"issue":"21","key":"10.1016\/j.semarthrit.2024.152460_bib0002","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.semarthrit.2024.152460_bib0003","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non\u2013Small-Cell Lung Cancer","author":"Wakelee","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152460_bib0004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1016\/j.semarthrit.2024.152460_bib0005","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.semarthrit.2024.152460_bib0006","series-title":"Common terminology criteria for adverse events v. 5.0","year":"2017"},{"key":"10.1016\/j.semarthrit.2024.152460_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer (1965)"},{"key":"10.1016\/j.semarthrit.2024.152460_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1197364","article-title":"Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases","volume":"14","author":"Ibis","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152460_bib0009","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nature Reviews Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152460_bib0010","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152460_bib0011","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.rdc.2020.03.002","article-title":"Cancer and Scleroderma","volume":"46","author":"Weeding","year":"2020","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.semarthrit.2024.152460_bib0012","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejca.2021.10.018","article-title":"Anti\u2013programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study","volume":"160","author":"Panhaleux","year":"2022","journal-title":"Eur J Cancer (1965)"},{"key":"10.1016\/j.semarthrit.2024.152460_bib0013","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152460_bib0014","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152460_bib0015","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152460_bib0016","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/art.39022","article-title":"Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:23:23Z","timestamp":1777472603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224001008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":16,"alternative-id":["S0049017224001008"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152460","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152460"}}